Condition: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) · Sponsor: French Innovative Leukemia Organisation
The goal of this clinical trial is to study the efficacy of the tagraxofusp + venetoclax combination in treatment-naive blastic plasmacytoid dendritic cell neoplasm adult patients. The main question is to verify the response in patients after 3 cycles of tagraxofusp+venetolax and to demonstrate if the combination of tagraxofusp + venetoclax increases the rate of complete remission, assessed after 3 months of treatment. Patients will receive a ramp-up phase of venetoclax during 3 days and at least 3 cycles of venetoclax. After, the investigators will evaluate the response, and depending on the response observed, patients may receive additional cycles of treatment for a maximum of 24 cycles, or receive an allograft or discontinue the treatment in the case of therapeutic failure.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| AMIENS - CH Amiens Picardie Site Sud | Amiens, France | Recruiting |
| ANGERS - CHU - Maladies du sang | Angers, France | Recruiting |
| ARGENTEUIL - Centre hospitalier Victor Dupouy | Argenteuil, France | Not Yet Recruiting |
| AVIGNON - Centre Hospitalier | Avignon, France | Not Yet Recruiting |
| BESANCON - Hôpital Jean Minjoz - Hématologie | Besançon, France | Recruiting |
| CLAMART - Hôpital d'Instruction des Armées de Percy | Clamart, France | Not Yet Recruiting |
| Clermont-Ferrand - Chu Estaing | Clermont-Ferrand, France | Not Yet Recruiting |
| Corbeil-Essonnes - Ch Sud Francilien | Corbeil-Essonnes, France | Not Yet Recruiting |
| AP-HP- CRETEIL - CHU Henri Mondor | Créteil, France | Recruiting |
| Grenoble CHU - Hématologie Clinique | Grenoble, France | Not Yet Recruiting |
| LILLE CHU - Hôpital Claude Huriez | Lille, France | Recruiting |
| Limoges CHU | Limoges, France | Not Yet Recruiting |
+ 22 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07007052